Stay updated on Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-05-01T03:20:55.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the removal of detailed information about the PENELOPE-B study and its objectives, while adding new references to the study's collaborators and a new version revision. The focus has shifted towards the CDK 4/6 inhibitor treatment and its implications for breast cancer patients.
    Difference
    55%
    Check dated 2025-04-16T14:24:50.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.0%
    Check dated 2025-04-09T09:15:47.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The page has updated the name of the organization from 'German Breast Group' to 'GBG Forschungs GmbH' and has also changed the software revision from v2.14.2 to v2.14.3.
    Difference
    0.5%
    Check dated 2025-04-01T23:21:09.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.8%
    Check dated 2025-02-24T21:15:34.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.8%
    Check dated 2025-02-10T10:14:36.000Z thumbnail image

Stay in the know with updates to Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page.